Status:
UNKNOWN
Cancer Panel From Blood of Lung Cancer Patients
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
MACROGEN
Conditions:
Non Small Cell Lung Cancer Metastatic
Non Small Cell Lung Cancer Recurrent
Eligibility:
All Genders
20+ years
Brief Summary
Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. This...
Detailed Description
This study is comprised of two cohorts as below: Cohort A: inoperable, untreated, non-small cell lung cancer patients Cohort B: non-small cell lung cancer patients who are in the treatment with targ...
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures, sampling, and analyses
- Pathologically confirmed non-small cell lung cancer
- Male or female, aged at least 20 years
- Matches one of two criteria :
- Cohort A: Patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy
- Cohort B: Patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent.
Exclusion
- Any concurrent and/or other active malignancy that has required treatment within 3 years
- Patients with mixed small cell histology
- Life expectancy less than 3 months
- Insufficient tissue for NGS test
Key Trial Info
Start Date :
March 10 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 10 2020
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03235765
Start Date
March 10 2017
End Date
March 10 2020
Last Update
January 22 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam, South Korea, 463-707